Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of a acetylcholinesterase levels.

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

Abstract: The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

Abstract: A method, a computer implemented method, and a device, all for adaptively testing a subjects neurological state. The method comprising the steps of: administering one or more seed questions; obtaining one or more answer(s) to the one or more seed questions; calculating a score value of a latent subject trait from the answers to the one or more seed questions; the method comprising an adaptive test loop, comprising: (a) selecting, based on the score value, one or more further questions from a bank of questions; (b) administering the one or more further questions to the subject; (c) updating the score value based on the answers to the one or more further questions; (d) determining whether a test completion criteria has been met; wherein the method repeats steps (a)-(d) in sequence until the test completion criteria has been met, and provides an output of the test based on the score value which is indicative of the subjects neurological state.

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

Abstract: The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT- containing dosage units and other compositions.

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

Abstract: A method of determining patient response to a neuropharmacological intervention, a method of determining a patient's likelihood of developing one or more neurological disorders, and systems for the same. The method of determining a patients likelihood of developing one or more neurological disorders, comprising the steps of: obtaining data indicative of electrical activity within the brain of the patient; generating a network, based at least in part on the obtained data, said network comprising a plurality of nodes and directed connections between nodes, wherein the network is indicative of a flow of the electrical activity within the brain of the patient; calculating, for each node, a difference in a number and/or strength of connections into the node and a number and/or strength of connections out of the node; and determining, using the calculated differences, the patients likelihood of developing one or more neurological disorders.

Abstract: This invention relates to methods and systems for determining network connections. It is particularly, but not exclusively, related to methods and systems for determining network connections in sparse networks, and has particular application to EEG data. An aspect of the invention provides a method for identifying, in a network of interacting nodes simultaneously producing signals, connections between said nodes and of estimating connection coefficients between nodes identified as connected which includes the steps of setting to zero connection coefficients where the calculated coherence or partial coherence is below a first predetermined threshold and subsequently setting to zero connection coefficients where the estimated connection coefficients are below a second predetermined threshold, and then re-estimating the connection coefficients for the combinations of nodes for which the connection coefficients have not already been set to zero.

Abstract: The invention describes improved treatments for Frontotemporal dementia based on the use of a methylthioninium compound in combination with a compound which directly modifies synaptic neurotransmission in the brain, such as a symptomatic Alzheimer's disease treatment (e.g. acetylcholinesterase and/or memantine).

Abstract: The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.

Abstract: The invention describes improved treatments for Frontotemporal dementia based on the use of a methylthioninium compound in combination with a compound which directly modifies synaptic neurotransmission in the brain, such as a symptomatic Alzheimer's disease treatment (e.g. acetylcholinesterase and/or memantine).

Abstract: This invention relates to methods and systems for determining network connections. It is particularly, but not exclusively, related to methods and systems for determining network connections in sparse networks, and has particular application to EEG data. An aspect of the invention provides a method for identifying, in a network of interacting nodes simultaneously producing signals, connections between said nodes and of estimating connection coefficients between nodes identified as connected which includes the steps of setting to zero connection coefficients where the calculated coherence or partial coherence is below a first predetermined threshold and subsequently setting to zero connection coefficients where the estimated connection coefficients are below a second predetermined threshold, and then re-estimating the connection coefficients for the combinations of nodes for which the connection coefficients have not already been set to zero.